Vaccinogen is a cancer vaccine company that is clinically testing OncoVAX®, a treatment designed to prevent the recurrence of colon cancer and potentially other solid tumors. The patented process leverages a patient’s own live tumor cells to launch a broad immune response against minimal residual disease. Vaccinogen believes that OncoVAX®, at an optimal dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in preventing cancer recurrence after surgical resection by addressing the diversity of cancer cells inherent to each patient’s tumor. Five clinical studies of OncoVAX® have been completed to date. Vaccinogen expects to begin enrolling patients in a pivotal phase 3b trial under an FDA Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) when adequate funding is obtained. For more information, visit the company’s website at www.vaccinogeninc.com.